Although it does not exhibit discernable cardiac toxicity, the new ALK5 inhibitor galunisertib produced only modest therapeutic responses in pancreatic cancer and HCC in phase II trials40–42. Here, TGFBR1 is linked to hepatocellular carcinoma.